Inhibitor Therapeutics Updates FDA Strategy for Itraconazole

A revised endpoint framework and a request to use historical placebo data as an external control signal how Inhibitor Therapeutics is navigating one of the more complex regulatory paths in rare oncology: a single-arm dataset seeking FDA alignment against a randomized precedent it did not generate. For regulatory affairs leads tracking novel efficacy endpoint negotiations, the BCCNS program offers a working case study.

The Tampa-based biotech disclosed the strategy update in its Form 10-Q filed August 14, 2026, alongside a descriptive characterization of prospectively collected lesion data from the completed Phase IIb HP2001 study. The proposed primary efficacy endpoint is surgically eligible basal cell carcinomas, tumors reaching the size threshold at which surgical removal would ordinarily be indicated. That endpoint was used in the randomized, placebo-controlled Tang study of vismodegib in Gorlin Syndrome, where active treatment reduced both new surgically eligible tumor development and performed patient surgeries. Vismodegib also holds FDA approval for advanced basal cell carcinoma based on single-arm response data, giving the company two distinct regulatory precedents to reference in its current FDA dialogue.

Applying Tang's site-based surgical thresholds to HP2001's prospectively collected measurements identified 258 surgically eligible baseline tumors. Descriptive analysis of those tumors showed a 52.7% objective response rate, 87.2% disease control, and a mean best reduction in longest diameter of 40.4% across 38 enrolled patients and 477 tracked target lesions. On the new-lesion side, 10 surgically eligible tumors arose across seven patients during 37.77 patient-years of on-treatment exposure, yielding a descriptive rate of 0.265 per patient-year. The Tang study reported approximately 29 new surgically eligible tumors per patient-year on placebo and approximately 2 per patient-year on vismodegib, a numerical separation that forms the basis of Inhibitor's request for FDA guidance on using the Tang placebo arm as an external control for the HP2001 new-lesion endpoint.

The cross-trial comparison is descriptive and does not constitute an adjusted treatment-effect estimate, a distinction the company acknowledges. Context from the Gorlin Syndrome Alliance Voice of the Patient report is also cited: 70% of respondents ranked preventing new BCCs among their top three desired outcomes, and 94% indicated that a 30% reduction in new basal cell carcinomas without significant side effects would represent a meaningful improvement over current options. The observed HP2001 rate sits well below that patient-defined threshold, though the company appropriately frames this as supportive context rather than a comparative efficacy claim.

A proposed commercial formulation, a new provisional patent filing, and continued FDA engagement are also noted in the 10-Q as concurrent workstreams. How FDA responds to the external control request and the surgically eligible BCC endpoint proposal will determine whether HP2001 data can anchor a registration-enabling study design.

Source: Inhibitor Therapeutics, Inc. via GlobeNewswire, September 8, 2026.